RT Journal Article
SR Electronic
T1 Vitamin D levels and COVID-19 severe pneumonia: a prospective case-control study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.10.24308690
DO 10.1101/2024.06.10.24308690
A1 Cardoso, Fortunato José
A1 Araújo, Carla Adriane Leal de
A1 Silva Junior, José Roberto da
A1 Guimarães, Angélica
A1 Taveiro, Michelle Viana
A1 Figueiroa, José Natal
A1 Bezerra Alves, João Guilherme
YR 2024
UL http://medrxiv.org/content/early/2024/06/11/2024.06.10.24308690.abstract
AB Introduction The hypothesis that a low vitamin D levels is associated with a higher risk for severe COVID-19 has not been completely proven, especially with severe pneumonia.Objective The goal of this study was to confirm the link between vitamin D levels and COVID-19 severe pneumonia.Methods This prospective case-control study involved 307 patients who developed severe SARS-CoV-2 pneumonia and were hospitalized in an intensive care unit. Age- and sex-matched controls (307) were selected from the same population; 307 patients with mild to moderate forms of COVID-19 who were not hospitalized. Vitamin D levels were assessed during the duration of the disease.Results The mean vitamin D level was lower in the severe COVID-19 pneumonia group as compared to the control group; 26.8 ± 7.6 ng/mL vs 28.6 ± 7.4 ng/mL, p<0.002. There were more patients with a sufficient level of vitamin D in the control group as compared to the control group; 127 (20.6%) vs 89 (14.5%), p<0.001. Multivariable analysis showed that a deficient vitamin D level was associated with a higher risk for severe COVID-19 pneumonia (OR=3.0; 95% CI: 1.79, 5.10CI), p<0.001.Conclusion A sufficient vitamin D level is linked to a lower risk of COVID-19 severe pneumonia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCNPq (Brazilian National Council for Scientific and Technological Development), grant number 401907/2020-1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was previously approved by the Research Ethical Committee of Instituto de Medicina Integral Prof. Fernando Figueira (IMIP). CAAE: 40857920.0.0000.5201.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors